Effect of Add-on L-Arginine Therapy on Heart Failure Patients
ConditionHeart Failure
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age19+
SponsorGerman University in Cairo
About this trial
Heart failure is considered one of the greatest challenges globally. There are various treatment strategies for heart failure. L-Arginine is an amino acid that was found to have beneficial effect on vasculature. This study aims to study the benefits and side effects of using L-arginine on the patients with ejection fraction \<40%
Eligibility criteria
Qualifiers
Patients with EF <40%
eGFR >30 mL/min/1.73 m2
Stable patients
Capable and willing to provide written consent
Disqualifiers
Patients with implantable cardioverter-defibrillator
Pregnant or lactating fmeales
Patients with a history of sensitivity to L-Arginine or any of the excipients
Acute heart failure patients
Trial design
Treatments tested in this trial
- L-Arginine Powder
- Placebo
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
German University in Cairo
Lead sponsor
Ain Shams University
Collaborator
Source ClinicalTrials.gov